

XX New serine protease expressed in brain tissue - used in screening
PT for potential serine protease inhibitors for drug use
XX Example 1; Page 51-54; 69pp; Japanese.

CC The present sequence is a serine protease designated BSSP-3, which
CC is isolated from mouse brain tissue. Transformants may be used to
CC produce the enzyme or its partial sequences; products from the present
CC invention are used for screening for potential peptide or non peptide
CC serine protease inhibitors or expression regulators for use as drugs.
XX Sequence 761 AA;

Query Match 91.7%; Score 1298; DB 20; Length 761;
Best Local Similarity 90.3%; Pred. No. 7.4e-108; Matches 232; Conservative 12; Mismatches 13; Indels 0; Gaps 0;
Matches 232; Conservative 12; Mismatches 13; Indels 0; Gaps 0;

Qy 1 CGLRLHLRQRKIGGKNSLRLGEWPWQSLRKSSHGDRLGATLSSCVVLTAAHCF 60
Db 505 girlhrqrkriiggnsirrgawpqslrlsahgdrligatllscvvttaahcf 564

Qy 61 KRYGNSTRSYAVRYGYDHTLVPEEEETGQQOIVIHEYRPDRSDYDIALYVRLOGPBEQ 120
Db 565 krygnnsrsvavrvgydhtlvpeefeqigqgivihnrprdsydiaalvlgqgeq 624

Qy 121 CARFESSHVLPACLPILWRERPKTASNCYITGGEDTGRAYSRQALPLLEKRFCEERY 180
Db 625 caristhvlpaclpwrerpktaasnchtgwdtgraystrlqaavplkrfrctery 684

Qy 181 KGRFTGRLCAGNLHEHKRVDSGCGDGPMLCERPGESWWVYGTSMGYGGVKDSPGV 240
Db 685 kgltgrmrcagnlqednrvdscqgdsgggplmeekpdeswvyygtswyggvkdtpgv 744

Qy 241 YTKVSAFPWIKSVTKL 257
Db 745 ytrvpafpwiksvtsl 761

RESULT 4

AAW83362 standard; Protein: 761 AA.
ID AAW83362.
XX AC AAW83362;

XX DT 17-FEB-1999 (first entry)

XX DE Mouse neurotrypsin.

XX KW Mouse; neurotrypsin; tumour inhibition; neurological disease;
KW lung disease; gene therapy; drug development; stroke; brain injury;
KW neurodegeneration; neuroinflammatory disease; multiple sclerosis;
KW epilepsy; hypoxia; ischaemia; nerve transection; neoangiogenesis;
KW emphysema; bronchitis.

XX OS Mus musculus.

XX PR 26-APR-1997; 97CH-0000966.
XX PA (SOND) SONDEREGGER P.

XX PF 24-APR-1998; 98WO-1B00625.

XX PR 26-APR-1997; 97CH-0000966.

XX PA (SOND) SONDEREGGER P.

XX DR WPI: 1999-009439/01.

DR N-PSDB; AAV72590.

XX PT New human and murine neurotrypsin - used, e.g. for inhibiting
PT tumours, treatment of neurological or lung disease, including by
PT gene therapy and in drug development
XX XX Claim 1; Page 29-32; 50pp; English.

CC The present sequence represents mouse neurotrypsin. Neurotrypsin proteins
CC and polynucleotides can be used: (i) to inhibit tumours, including
CC metastases, e.g. of brain or retina; (ii) to minimise tissue damage
CC caused by stroke or brain injury (having a protective effect on the
CC neuroinflammatory disease (e.g. multiple sclerosis) or epilepsy; (iv) to
CC increase survival of damaged neurons (e.g. in cases of hypoxia,
CC ischaemia, nerve transection) and to stimulate regeneration and/or
CC restoration of synapses; (v) to treat or prevent retinal disorders (e.g.
CC degeneration or neoangiogenesis); (vi) to prevent apoptosis (or other
CC causes of cell death) in the nervous system; (vii) to regenerate brain
CC and/or nervous tissue; (viii) to treat pain; (ix) to improve brain
CC performance, including learning and memory; (x) to treat or prevent a
CC wide range of psychiatric disorders; and (xi) to treat brain or lung
CC injury associated with protease expression (specifically emphysema or
CC bronchitis).
XX SQ Sequence 761 AA;

Query Match 91.7%; Score 1298; DB 20; Length 761;
Best Local Similarity 90.3%; Pred. No. 7.4e-108; Matches 232; Conservative 12; Mismatches 13; Indels 0; Gaps 0;

Qy 1 CGLRLHLRQRKIGGKNSLRLGEWPWQSLRKSSHGDRLGATLSSCVVLTAAHCF 60
Db 505 cglrlhrqrkriiggnsirrgawpqslrlsahgdrligatllscvvttaahcf 564

Qy 121 KRYGNSTRSYAVRYGYDHTLVPEEEETGQQOIVIHEYRPDRSDYDIALYVRLOGPEEQ 120
Db 565 krygnnsrsvavrvgydhtlvpeefeqigqgivihnrprdsydiaalvlgqgeq 624

Qy 181 KGRFTGRLCAGNLHEHKRVDSGCGDGPMLCERPGESWWVYGTSMGYGGVKDSPGV 240
Db 685 kgltgrmrcagnlqednrvdscqgdsgggplmeekpdeswvyygtswyggvkdtpgv 744

Qy 241 YTKVSAFPWIKSVTKL 257
Db 745 ytrvpafpwiksvtsl 761

Qy 121 CARFESSHVLPACLPILWRERPKTASNCYITGGEDTGRAYSRQALPLKRFCEERY 180
Db 625 caristhvlpaclpwrerpktaasnchtgwdtgraystrlqaavplkrfrctery 684

Qy 181 KGRFTGRLCAGNLHEHKRVDSGCGDGPMLCERPGESWWVYGTSMGYGGVKDSPGV 240
Db 685 kgltgrmrcagnlqednrvdscqgdsgggplmeekpdeswvyygtswyggvkdtpgv 744

Qy 241 YTKVSAFPWIKSVTKL 257
Db 745 ytrvpafpwiksvtsl 761

RESULT 5
AAR09227
ID AAR09227 standard; protein: 526 AA.
XX AC AAR09227;
XX DT 24-FEB-1993 (first entry)
XX DE t-PA deletion variant d303.
XX KW Tissue plasminogen activator; zymogen; clot; plasma; plasmin.
XX OS Homo sapiens.
XX DF 24-FEB-1993
XX DE t-PA deletion variant d303.
XX FT Misc-difference 302..303
XX FT /label= "the amino acid at position 303 of the
XX FT /note= "wild-type mature t-PA has been deleted"
XX PN WO9002798-A.

Result No.	Score	Query Match	Length	DB ID	Description
1	4905	100.0	875	20 AAW83361	Human neurotrypsin
2	4617	94.1	822	20 AAW9087	Human serine protease
3	3481	71.0	761	20 AAW9088	Mouse serine protease
4	3481	71.0	761	20 AAW83362	Mouse neurotrypsin
5	983.5	20.1	1785	19 AAW64591	Human SRCR protein
6	830	16.9	1436	22 AAB66088	Bovine WCL protein
7	822.5	16.8	1413	22 AAB66039	Human TANCO 234 ma
8	822.5	16.8	1453	22 AAB66037	Human TANCO 234 ex
9	820.5	16.7	1319	22 AAB66040	Rat von Ebner's gland polypeptide isolat
10	690.5	14.1	1290	18 AAW07609	New human and murine neurotrypsin - used, e.g. for inhibiting
11	645.5	13.2	757	21 AAB19127	

Human liver cell c
Human scavenger receptor
Amino acid sequenc
Human PRO229 proteo
Clone HOPEC94 #1.
Human Lysyl oxidase
Human Lysyl oxidase
Human secreted protein
Murine Lysyl oxidase
Human SRCR protein
Hybrid plasminogen
Hybrid plasminogen
PA mutant Pig 1-54
Mouse Serine Protease
Tissue plasminogen
Human serine protease
Human plasminogen
Plasminogen mitein
Tissue plasminogen
Plasminogen mitein
Human 'Glu' plasma
Sequence encoded by
Plasminogen protein
Plasminogen mitein
Plasminogen mitein
Plasminogen mitein
Plasminogen mitein
Plasminogen mitein
Human plasminogen
Human plasminogen
Human Plasminogen
Human Plasminogen
Human Plasminogen
SEQ ID 77 of WO991
AAW64537
AAW68200
AAV13369
AAB80237
AAB19534
AAB00077
AAB00073
AAB13307
AAB00078
AAP64590
AAP80591
AAP80592
AAR20013
AAR90179
AAR20113
AAR012914
AAR60519
AAR34427
AAR34426
AAW34385
AAR12948
AAR90179
AAR12939
AAR12939
AAR12939
AAR12943
AAR12944
AAB01887
AAY99589
AAY50867
AAR08065
AAY08685
AYX02114
AAW3361 standard; Protein: 875 AA.
ID AAW83361
XX
AC AAW83361;
XX
DT 17-FEB-1999 (first entry)
XX
DE Human neurotrypsin.
XX
KW Human; neurotrypsin; tumour inhibition; neurological disease;
lung disease; gene therapy; drug development; stroke; brain injury;
neurodegeneration; neuroinflammation; multiple sclerosis;
epilepsy; hypoxia; ischaemia; nerve transection; neangiogenesis;
empysema; bronchitis.
XX
OS Homo sapiens.
XX
PN WO9949322-A1.
XX
PD 05-NOV-1998.
XX
PF 24-APR-1998;
XX
PR 26-APR-1997;
XX
PA (SOND/.) SONDEREGGER P.
XX
PI Sonderegger P;
XX
DR WPI: 1999-009438/01.
DR N-PSDB; AAV72559.
XX
PT New human and murine neurotrypsin - used, e.g. for inhibiting

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: July 17, 2001, 16:52:11 ; Search time 37.5 Seconds
(without alignments)
1414.560 Million cell updates/sec

Title: US-09-403-724-2
Perfect score: 4905

Sequence: MTIARFVLAALIGALPEVVG.....PSVYTAKVSAFPWIKSVTKL 875

Scoring table: BLOSUM62

Gapon 10.0 , Gapext 0.5

Searched: 412676 seqs, 60623988 residues

Total number of hits satisfying chosen parameters:

Minimum DB seq length: 0

Maximum DB seq length: 20000000000

Post-processing: Minimum Match 100%

Maximum Match 100%

Listing first 45 summaries

Database : A_Geneseq_0601:*

1: /SIDSB8/geodata/geneseq/geneseqp/AA1980.DAT:*

2: /SIDSB8/geodata/geneseq/geneseqp/AA1981.DAT:*

3: /SIDSB8/geodata/geneseq/geneseqp/AA1982.DAT:*

4: /SIDSB8/geodata/geneseq/geneseqp/AA1983.DAT:*

5: /SIDSB8/geodata/geneseq/geneseqp/AA1984.DAT:*

6: /SIDSB8/geodata/geneseq/geneseqp/AA1986.DAT:*

7: /SIDSB8/geodata/geneseq/geneseqp/AA1987.DAT:*

8: /SIDSB8/geodata/geneseq/geneseqp/AA1988.DAT:*

9: /SIDSB8/geodata/geneseq/geneseqp/AA1989.DAT:*

10: /SIDSB8/geodata/geneseq/geneseqp/AA1990.DAT:*

11: /SIDSB8/geodata/geneseq/geneseqp/AA1991.DAT:*

12: /SIDSB8/geodata/geneseq/geneseqp/AA1992.DAT:*

13: /SIDSB8/geodata/geneseq/geneseqp/AA1993.DAT:*

14: /SIDSB8/geodata/geneseq/geneseqp/AA1994.DAT:*

15: /SIDSB8/geodata/geneseq/geneseqp/AA1995.DAT:*

16: /SIDSB8/geodata/geneseq/geneseqp/AA1996.DAT:*

17: /SIDSB8/geodata/geneseq/geneseqp/AA1997.DAT:*

18: /SIDSB8/geodata/geneseq/geneseqp/AA1998.DAT:*

19: /SIDSB8/geodata/geneseq/geneseqp/AA1999.DAT:*

20: /SIDSB8/geodata/geneseq/geneseqp/AA2000.DAT:*

21: /SIDSB8/geodata/geneseq/geneseqp/AA2001.DAT:*

22: /SIDSB8/geodata/geneseq/geneseqp/AA2001.DAT:*

ALIGNMENTS

RESULT 1
AAW83361
ID AAW83361 standard; Protein: 875 AA.
XX
AC AAW83361;
XX
DT 17-FEB-1999 (first entry)
XX
DE Human neurotrypsin.
XX
KW Human; neurotrypsin; tumour inhibition; neurological disease;
lung disease; gene therapy; drug development; stroke; brain injury;
neurodegeneration; neuroinflammation; multiple sclerosis;
epilepsy; hypoxia; ischaemia; nerve transection; neangiogenesis;
empysema; bronchitis.
XX
OS Homo sapiens.
XX
PN WO9949322-A1.

XX
PD 05-NOV-1998.
XX
PF 24-APR-1998;
XX
PR 26-APR-1997;
XX
PA (SOND/.) SONDEREGGER P.
XX
PI Sonderegger P;
XX
DR WPI: 1999-009438/01.
DR N-PSDB; AAV72559.
XX
PT New human and murine neurotrypsin - used, e.g. for inhibiting

SUMMARIES

8
Human liver cell c
Human scavenger receptor
Amino acid sequenc
Human PRO229 proteo
Clone HOPEC94 #1.
Human Lysyl oxidase
Human Lysyl oxidase
Human secreted protein
Murine Lysyl oxidase
Human SRCR protein
Hybrid plasminogen
Hybrid plasminogen
PA mutant Pig 1-54
Mouse Serine Protease
Tissue plasminogen
Human serine protease
Human plasminogen
Plasminogen mitein
Tissue plasminogen
Plasminogen mitein
Human 'Glu' plasma
Sequence encoded by
Plasminogen protein
Plasminogen mitein
Plasminogen mitein
Plasminogen mitein
Plasminogen mitein
Plasminogen mitein
Human plasminogen
Human plasminogen
Human Plasminogen
Human Plasminogen
Human Plasminogen
SEQ ID 77 of WO991
AAW64537
AAW68200
AAV13369
AAB80237
AAB19534
AAB00077
AAB00073
AAB13307
AAB00078
AAP64590
AAP80591
AAP80592
AAR20013
AAR90179
AAR20113
AAR12914
AAR60519
AAR34427
AAR34426
AAW34385
AAR12948
AAR90179
AAR12939
AAR12939
AAR12939
AAR12943
AAR12944
AAB01887
AAY99589
AAY50867
AAR08065
AAY08685
AYX02114
AAW3361 standard; Protein: 875 AA.
ID AAW83361
XX
AC AAW83361;
XX
DT 17-FEB-1999 (first entry)
XX
DE Human neurotrypsin.
XX
KW Human; neurotrypsin; tumour inhibition; neurological disease;
lung disease; gene therapy; drug development; stroke; brain injury;
neurodegeneration; neuroinflammation; multiple sclerosis;
epilepsy; hypoxia; ischaemia; nerve transection; neangiogenesis;
empysema; bronchitis.
XX
OS Homo sapiens.
XX
PN WO9949322-A1.

KW	autoantibody; ss.	Qy	394 GSHEGRLEVYYRGQMGTVYDDGWTTELNTYVVCROLGFYKQOASAN-HFEESTGPPIWLDD 452
XX	Homo sapiens.	Db	888 drcrerverlyqgwgtvcdywtndanvvcrgewamsapnafqggsqpvivid 947
OS		Qy	453 VSCSGKETRFLOCSRROWGRHDCSHREDVSIACYPGGE-----
XX	WO9830687-A2.	Db	948 vrcsghesylwscphngwlsncggghedavicsaaqsqstprpdwltntipaltvgs 1007
PN		Qy	494 LSLGFPPVRLLMDGENKKEGRYEVFINGQWTICDDGWTDKDAAVICROLGYKGPARARTMA 553
XX	PD 16-JUL-1998.	Db	1008 ssia--lrlynggdcrgrevevlyrgswgtvcdswtdndanvrcrlgqwmawsgpna 1065
PF	09-JAN-1998;	Qy	554 YFGEGKGPITHDNVKRCTGNERSLADCIKODIGRINCRHSEDAVGTC-----
XX	98WO-DE000096.	Db	1066 rfgqsgspivddvcesqnesylwcpchgwithncgnhedavicsatqinsttdw 1125
XX	18-JUL-1997;	Qy	604 KKAISGNKESLSSVCLRLHRRKRIGG-----
PR	97DE-103097.	Db	1126 PTTTtarP--ssncggfity-----
XX	09-JAN-1997;	Qy	647 -----SLRKSSHG-----
PR	97DE-100059.	Db	1177 nlgsnkleahncsfdyveifdgslmssllkgic-----
PA	(DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.	Qy	693 GDYHTLVPEEEIGYQQLYTHREYRPDRSDYDIALVRIQGPPEOCARFSHVLPACIP 752
XX	PA Mollenhauer J, Poustka A;	Db	1222 ssynrmrt-ihfrsdifqntflawmnspsdatrlrvlnlnsyglca-----
XX	WPI; 1998-399136/34.	Qy	753 LWRRPQXTASNCYING-WGDTGRAYSRATLQQAAIPPLPKRFCEERYKGRTGRMLCACGN 811
DR		Db	1269 -----grveyihgtwg-tvcdswtigaev -----
XX	N-PSDB; AA49652.	Qy	812 LHEHKRVSDCQGDGSPGPU-----
PT	Proteins containing scavenger receptor, cysteine rich domain -	Db	1311 ay-----fgsgsgpitolddvecsgtestlwqcrnrw-----fshnchhreda 1353
XX	useful for diagnosis and treatment of tumours	Qy	857 GV 858
PS	PT Claim 2; 54pp; German.	Db	1354 gv 1355
XX		RESULT 6	
CC	This sequence represents a human protein which contains a SRCR (scavenger receptor, cysteine rich) domain. The gene and encoded protein can be used to diagnose or treat tumours, particularly of the nervous system (medullo-blomastoma or glioma) or breast. The DNA sequence and probes derived from it, are used to identify genes that express SRCR-domain containing proteins, to determine the form in which these proteins exist and to assess the significance of individual forms on cellular properties. The protein can be used to detect the presence of autoantibodies and antibodies which regulate its expression.	ID	AAB66088 standard; Protein; 1436 AA.
CC	Sequence 1785 AA;	XX	AAB66088;
CC	SQ	XX	30-MAR-2001 (first entry)
CC	Query Match 20 1%; Score 983.5; DB 19; Length 1785;	XX	DE
CC	Best Local Similarity 28.8%; Pred. No. 4.7e-62;	XX	Bovine WCL protein.
CC	Matches 294; Conservative 92; Mismatches 353; Indels 283; Gaps 38;	XX	XX
Qy	20 GDPSVL----NDSLHHSHRSPPAGPHYPYLPTOQRPPTRPPPLPRPRPPRALPA 74	XX	Gene therapy; TANGO protein; INTERCEPT protein; neurological disorder; central nervous system; focal brain disorder; bipolar affective disorder; global-diffuse cerebral disorder; cerebrovascular; Alzheimer's disease; dementia; Huntington's disease; amyotrophic lateral sclerosis; Parkinson's; Gilles de la Tourette's syndrome; hypertension; sleep; neuropsychiatric; psychoactive substance use; anxiety.
Db	434 qyesylwscphngwlsncgħedaq-----vicsahswspdtlptlipastvgs 488	XX	XX
Qy	75 Q-----RHALQAGHTPRPHPMGCPAGEBPWTSVTDGAPCLR----WAE 114	XX	XX
Db	489 essalrlrvnggdrccgrvevygg-----sngtvcodsw-dtndanvvcrgpcgwam 541	XX	XX
Qy	115 VPP----FLERSPPASAQLORHNFRCRSPDGAGRVP-----CFYGDARGKV- 158	XX	XX
Db	542 sappgnarfgsgpilvdidrsqsghe-----sypscphngwlsncgħedavic 593	XX	XX
Qy	159 -----DWGTYCDCRHGS-----VRLRGCKNEFFECTVEYASGWGTVYCSS 197	XX	XX
Db	594 sasqsrptpsdtw----ptshastagsesslairlvnggdrccgrvevlyrgswgtvodd 650	XX	XX
Qy	198 HWDSDASVICHOLQLOGKGIAKOPF-----GIGHIPIWNYRCRGDEENILCEIDW 254	XX	XX
Db	651 ywdtn danvrcrlgq-----qcgwamsapnafqgqsgpvlvdvrcsgħesylwscphngw 707	XX	XX
Qy	255 OGGVCPORMAAAVTCSEFSHGPTFP-----IIRLAGSSVHEGRVL 295	XX	XX
Db	708 1shnċgħedagħavicsasqqtspdtwptshastagsesslairlvngdrcqgrrev 767	XX	XX
Qy	296 YHAGQWGTIVYDDOWDDA DAYEYCICROGLSGIAWAHQAYTEGEGSGSPVMDDEVROTGNELS 355	XX	XX
Db	768 lyzgswgtvcdywdtn danvrcrlgq-----vrlagġok 827	XX	XX
Qy	356 IEQPKSSWEHNGHAKEDAGVSC-----TPLIDG-----VRLAGġok 393	XX	XX
Db	828 lyzgswgtvcdywdtn danvrcrlgq-----vrlagġok 887	XX	XX

		xx SQ	Sequence	347 AA;
QY	555 FGRGKGPITHDVNVKCTGNERSLADCIKDIGHNCRHSEDAGVIC 599			Query Match 13.1%; Score 643; DB 19; Length 347;
Db	301 ygpgvgrividnrvcsgeqslsqcgfhrgfdcthqedvavic 345			Best Local Similarity 40.0%; pred. No. 1.8e-38;
RESULT	1.3			Mismatches 45; Indels 48; Gaps 10;
AAN68200	Human scavenger receptor protein SP alpha.			
ID	AAN68200 standard; Protein; 347 AA.			
XX				
AC				
XX				
XX				
DT	07-DEC-1998 (first entry)			
XX				
DE	Human scavenger receptor protein SP alpha.			
XX	SP alpha; scavenger receptor; SROR; human; antibody; immunoassay;			
KW	immunomodulator; autoimmune disease; transplant rejection;			
KW	infection; tumour; immunodeficiency; therapy.			
XX				
OS	Homo sapiens.			
XX				
FH	Location/Qualifiers			
FT	Peptide 1..19			
FT	/label= Sig-peptide			
FT	Protein 20..347			
FT	/label= Mat_Protein			
FT	Domain 24..125			
FT	/note= "cysteine-rich domain"			
FT	Domain 138..239			
FT	/note= "cysteine-rich domain"			
FT	Domain 245..346			
FT	/note= "cysteine-rich domain"			
XX				
PN	W09830443-A1.			RESULT 14
XX				AAV13369
PD	11-SEP-1998.			ID AAV13369 standard; Protein; 347 AA.
XX				XX
PR	05-MAR-1998; 98WO-US04370.			AC AAV13369;
XX	06-MAR-1997; 97US-0039956.			XX
XX	(BRIM) BRISTOL-MYERS SQUIBB CO.			DT 25-JUN-1999 (first entry)
PA	Aruffo AA, Gebe JA, Siadak AW;			XX
PJ	DR WPI; 1998-495847/42.			DE Amino acid sequence of protein PRO229.
XX	N-PSDB; AA54605.			XX
PT	New scavenger receptor cysteine-rich protein - the antibodies of			Secreted protein; transmembrane protein; human; enterocolitis;
PT	which can be used to modulate the immune response			XX
XX				Zollinger-Ellison syndrome; gastrointestinal ulceration;
PS	Claim 7; Fig 1A-B; 46pp; English.			XX
XX	This is the amino acid sequence of a novel protein (see AAW68200),			congenital microvilli atrophy; skin disease; cell growth;
CC	termed SP alpha, that is a member of the scavenger receptor			XX
CC	cysteine-rich (SRCR) family. The sequence was deduced from an			KW abnormal keratinocyte differentiation; psoriasis; epithelial cancer;
CC	isolated cDNA clone (see AAV54605). SP alpha transcripts are found			XX
CC	in human bone marrow, spleen, lymph node, thymus and foetal liver			KW Parkinson's disease; Alzheimer's disease; ALS; neuropathy;
CC	but not in non-lymphoid tissues. SP alpha has the same domain			XX
CC	organisation as the extracellular region of C5 and CD6 and is			KW fibromodulin; dermal scarring; User Syndrome; Atrophia areata;
CC	composed of 3 SRCR domains. It is capable of binding to cells of			XX
CC	the monocytic lineage, and appears to be involved in the regulation			KW anti-thrombotic; wound healing; tissue repair.
CC	of monocyte activation, function and/or survival, and is therefore			XX
CC	an important component in the immunoregulatory system. Methods of			OS Homo sapiens.
CC	recombinantly producing SP alpha are disclosed. In addition,			XX
CC	antibodies reactive with SP alpha are provided, as are methods of			PN W09914328-A2.
CC	using antibodies that bind to SP alpha for modulating the			XX
CC	interaction between SPalpha and its receptor. SP alpha can be used			PD 25-MAR-1999.
CC	in pharmaceutical compositions to regulate the immune response in,			PF 16-SEP-1998; 98WO-US19330.
CC	for example, autoimmune diseases, viral infections, transplant			XX
CC	rejection suppression, tumour cell proliferation suppression, and			25-NOV-1997; 97US-0059121.
CC	combined variable immunodeficiency.			PR 17-SEP-1997; 97US-0059113.
CC				PR 17-SEP-1997; 97US-0059115.
CC				PR 17-SEP-1997; 97US-0059117.
CC				PR 17-SEP-1997; 97US-0059119.
CC				PR 17-SEP-1997; 97US-0059122.
CC				PR 17-SEP-1997; 97US-0059124.
CC				PR 17-SEP-1997; 97US-0059184.
CC				PR 18-SEP-1997; 97US-0059163.
CC				PR 18-SEP-1997; 97US-0059266.
CC				PR 15-OCT-1997; 97US-0062125.
CC				PR 17-OCT-1997; 97US-0062285.
CC				PR 17-OCT-1997; 97US-0062287.
CC				PR 21-OCT-1997; 97US-0063486.

PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A,
 PI Godowski PJ, Grimaldi CJ, Gurney AJ, Hillian KJ, Klijavin IJ;
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
 PI Williams PM, Wood WI;
 XX
 DR WPI: 2001-081051/09.
 N-PSDD; AAF72398.

XX Sixty one nucleic acids encoding PRO polypeptides which are useful in
 PT the treatment of skin diseases (e.g. psoriasis), cancers (e.g. lung
 PT squamous cell carcinoma) and neurodegenerative diseases (e.g.
 PT Alzheimer's disease).
 XX

PS Claim 1; Fig 54; 393pp; English.

XX The present sequence is one of sixty one novel secreted and
 CC transmembrane PRO polypeptides. The PRO polypeptides are
 CC useful for treating skin diseases (e.g. psoriasis), cancers (e.g. lung
 CC squamous cell carcinoma), gastrointestinal disorders (e.g.
 CC enterocolitis), neurodegenerative diseases (e.g. Alzheimer's disease,
 CC Parkinson's disease), wound repair, cardiovascular disorders (e.g.
 CC endometrial bleeding angiogenesis, ischaemias such as coronary
 CC ischaemia, atherosclerosis), inflammatory disorders (e.g. asthma,
 CC rheumatoid arthritis, multiple sclerosis), infertility, AIDS and
 CC diabetes and retinal disorders such as retinitis pigmentosum.
 CC The PRO nucleic acids have applications in molecular biology, including
 CC use as hybridization probes, and in chromosome and gene mapping.
 XX

SQ Sequence 347 AA;

	Query Match	Best Local Similarity	Score	Length
Matches	138; Conservative	40.0%; 45; Mismatches	643; DB 222; Pred. No. 1.8e-38;	347;
Qy	280 IRLAGGSVHEGRVELYHAGGNGTVCDQWIDDAEVICROLGLSIAKAWHQAYFGEGS	414; Indels	114; 48; Gaps	10;
Db	24 vrlvgghrcrgevveqkqgwgtveddgwikkavtclrgcg-----aaagtp	75		
Qy	340 G-----PVMLEVRCTGNELTEQPKSSMGEHNHKEDAGVS-----TP	339		381
Db	76 gilyeppakeqkvlivsvctgtdiaqeqee--vyddshdedagascenpessfsp	133		
Qy	382 LTDGVIRLAGGKGSHEGRLEVYYRQWGTVCDDGNTTELNTYVCROLGFKYK-----OAS	437		
Db	134 vpegv-rladgphckarvevhqngwytvctgwsiraavlvcrig--egravitqkr	190		
Qy	438 ANHFEESTGPWLDVSCSGKETRFLOCNSROWGRHDCSHEDDVSTACYPGEGERLSSLG	497		
Db	191 cnkbaygrkpwiwqsmcsqreatlqdcpsspwgkntcnhdtwrced-----p	241		
Qy	498 FPYRLMDGINKKREGREVEFINGWGTCDGGTIDKDAVICRQLGKGPARA--RTMAY	554		
Db	242 fairlvgdnllcsgrllevlkqwgswcdnngekedqvvcqkqgc-qks1spsfdrkc	300		
Qy	555 FGEGKGKPIHVDNYKCTGNERSLADCIKODIGRHNCRSSEDAVGIC	599		
Db	301 ygpvgriwlndvrcsgeeqs1eqcqhrfwgfdctnqdvavic	345		